EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 38 / No 5 (Mai 2022) Med Sci (Paris), 38 5 (2022) 438-444 References
Open Access
Issue
Med Sci (Paris)
Volume 38, Number 5, Mai 2022
Page(s) 438 - 444
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2022055
Published online 24 May 2022
  1. Millard M, Odde S, Neamati N, Integrin Targeted Therapeutics. Theranostics 2012 ; 1 : 154–188. [Google Scholar]
  2. Nguyen TP, Qu Z, Weiss JN, Cardiac fibrosis and arrhythmogenesis: The road to repair is paved with perils. J Mol Cell Cardiol 2014 ; 70 : 83–91. [CrossRef] [PubMed] [Google Scholar]
  3. de Boer RA, de Keulenaer G, Bauersachs J, et al. Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. Eur J Heart Fail 2019 ; 21 : 272–285. [CrossRef] [PubMed] [Google Scholar]
  4. González A, Ravassa S, López B, et al. Myocardial remodeling in hypertension toward a new view of hypertensive heart disease. Hypertension 2018 ; 72 : 549–558. [CrossRef] [PubMed] [Google Scholar]
  5. Cleutjens JPM, Verluyten MJA, Smits JFM, et al. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol 1995 ; 147 : 325–338. [PubMed] [Google Scholar]
  6. Möllmann H, Nef HM, Kostin S, et al. Bone marrow-derived cells contribute to infarct remodelling. Cardiovasc Res 2006 ; 71 : 661–671. [CrossRef] [PubMed] [Google Scholar]
  7. Kramann R, Schneider RK, Dirocco DP, et al. Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell 2015 ; 16 : 51–66. [CrossRef] [PubMed] [Google Scholar]
  8. Von Gise A, Pu WT., Endocardial and epicardial epithelial to mesenchymal transitions in heart development and disease. Circ Res 2012 ; 110 : 1628–1645. [CrossRef] [PubMed] [Google Scholar]
  9. Travers JG, Kamal FA, Robbins J, et al. Cardiac fibrosis: The fibroblast awakens. Circ Res 2016 ; 118 : 1021–1040. [CrossRef] [PubMed] [Google Scholar]
  10. Yaniz-Galende E, Roux M, Nadaud S, et al. Fibrogenic Potential of PW1/Peg3 Expressing Cardiac Stem Cells. J Am Coll Cardiol 2017 ; 70 : 728–741. [CrossRef] [PubMed] [Google Scholar]
  11. Wynn TA, Ramalingam TR, Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat Med 2012 ; 18 : 1028–1040. [CrossRef] [PubMed] [Google Scholar]
  12. Ma ZG, Yuan YP, Wu HM, et al. Cardiac fibrosis: New insights into the pathogenesis. Int J Biol Sci 2018 ; 14 : 1645–1657. [CrossRef] [PubMed] [Google Scholar]
  13. Kai H, Kuwahara F, Tokuda K, et al. Diastolic dysfunction in hypertensive hearts: Roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 2005 ; 28 : 483–490. [CrossRef] [PubMed] [Google Scholar]
  14. Westermann D, Lindner D, Kasner M, et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Hear Fail 2011 ; 4 : 44–52. [CrossRef] [PubMed] [Google Scholar]
  15. Idris-Khodja N, Mian MOR, Paradis P, et al. Dual opposing roles of adaptive immunity in hypertension. Eur Heart J 2014 ; 35 : 1238–1244. [CrossRef] [PubMed] [Google Scholar]
  16. Patel B, Bansal SS, Ismahil MA, et al. CCR2+ Monocyte-Derived Infiltrating Macrophages Are Required for Adverse Cardiac Remodeling During Pressure Overload. JACC Basic to Transl Sci 2018 ; 3 : 230–244. [CrossRef] [Google Scholar]
  17. Bansal R, Nakagawa S, Yazdani S, et al. Integrin alpha 11 in the regulation of the myofibroblast phenotype: Implications for fibrotic diseases. Exp Mol Med 2017 ; 49. [Google Scholar]
  18. Henderson NC, Sheppard D, Integrin-mediated regulation of TGFβ in fibrosis. Biochim Biophys Acta - Mo Basis Dis 2013 ; 1832 : 891–896. [CrossRef] [Google Scholar]
  19. Bujak M, Ren G, Kweon HJ, et al. Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation 2007 ; 116 : 2127–2138. [CrossRef] [PubMed] [Google Scholar]
  20. Popov Y, Patsenker E, Stickel F, et al. Integrin αvβ6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol 2008 ; 48 : 453–464. [CrossRef] [PubMed] [Google Scholar]
  21. Hahm K, Lukashev ME, Luo Y, et al. Avβ6 Integrin Regulates Renal Fibrosis and Inflammation in Alport Mouse. Am J Pathol 2007 ; 170 : 110–125. [CrossRef] [PubMed] [Google Scholar]
  22. John AE, Graves RH, Pun KT, et al. Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosis. Nat Commun 2020; 11 : 1–14. [CrossRef] [PubMed] [Google Scholar]
  23. Horan GS, Wood S, Ona V, et al. Partial inhibition of integrin αvβ6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 2008 ; 177 : 56–65. [CrossRef] [PubMed] [Google Scholar]
  24. Munger JS, Huang X, Kawakatsu H, et al. The integrin αvβ6 binds and activates latent TGFβ1: A mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999 ; 96 : 319–328. [CrossRef] [PubMed] [Google Scholar]
  25. Reed NI, Jo H, Chen C, et al. The αvβ1 integrin plays a critical in vivo role in tissue fibrosis. Sci Transl Med 2015; 7. [Google Scholar]
  26. Bouvet M, Claude O, Roux M, et al. Anti-integrin αv therapy improves cardiac fibrosis after myocardial infarction by blunting cardiac PW1+ stromal cells. Sci Rep 2020; 10 : 1–15. [CrossRef] [PubMed] [Google Scholar]
  27. Mu D, Cambier S, Fjellbirkeland L, et al. The integrin ανβ8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-β1. J Cell Biol 2002 ; 157 : 493–507. [CrossRef] [PubMed] [Google Scholar]
  28. Klingberg F, Chow ML, Koehler A, et al. Prestress in the extracellular matrix sensitizes latent TGF-β1 for activation. J Cell Biol 2014 ; 207 : 283–297. [CrossRef] [PubMed] [Google Scholar]
  29. Hinz B., The extracellular matrix and transforming growth factor-β1: Tale of a strained relationship. Matrix Biol 2015 ; 47 : 54–65. [CrossRef] [PubMed] [Google Scholar]
  30. Wipff PJ, Hinz B, Integrins and the activation of latent transforming growth factor β1 - An intimate relationship. Eur J Cell Biol 2008 ; 87 : 601–615. [CrossRef] [PubMed] [Google Scholar]
  31. Hinz B., It has to be the αv: Myofibroblast integrins activate latent TGF-β1. Nat Med 2013 ; 19 : 1567–1568. [CrossRef] [PubMed] [Google Scholar]
  32. Ulmasov B, Neuschwander-Tetri BA, Lai J, et al. Inhibitors of Arg-Gly-Asp-Binding Integrins Reduce Development of Pancreatic Fibrosis in Mice. Cmgh 2016 ; 2 : 499–518. [Google Scholar]
  33. Ulmasov B, Noritake H, Carmichael P, et al. An Inhibitor of Arginine-Glycine-Aspartate-Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis. Hepatol Commun 2019 ; 3 : 246–261. [CrossRef] [PubMed] [Google Scholar]
  34. Henderson NC, Arnold TD, Katamura Y, et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 2013 ; 19 : 1617–1624. [CrossRef] [PubMed] [Google Scholar]
  35. Murray IR, Gonzalez ZN, Baily J, et al. Av Integrins on Mesenchymal Cells Regulate Skeletal and Cardiac Muscle Fibrosis. Nat Commun 2017; 8. [PubMed] [Google Scholar]
  36. Bagnato GL, Irrera N, Pizzino G, et al. Dual αvβ3 and avβ5 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis. Clin Sci 2018 ; 132 : 231–242. [CrossRef] [PubMed] [Google Scholar]
  37. Perrucci GL, Barbagallo VA, Corlianò M, et al. Integrin ανβ5 in vitro inhibition limits pro-fibrotic response in cardiac fibroblasts of spontaneously hypertensive rats. J Transl Med 2018 ; 16 : 1–13. [CrossRef] [PubMed] [Google Scholar]
  38. Ikeuchi M, Tsutsui H, Shiomi T, et al. Inhibition of TGF-β signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 2004 ; 64 : 526–535. [CrossRef] [PubMed] [Google Scholar]
  39. Schnittert J, Bansal R, Storm G, et al. Integrins in wound healing, fibrosis and tumor stroma: High potential targets for therapeutics and drug delivery. Adv Drug Deliv Rev 2018 ; 129 : 37–53. [CrossRef] [PubMed] [Google Scholar]
  40. Eijgenraam TR, Silljé HHW, de Boer RA. Current understanding of fibrosis in genetic cardiomyopathies. Trends Cardiovasc Med 2020; 30 : 353–61. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.